ArticleEuropean journal of case reports in internal medicine2025
Anabolic-Androgenic Steroid-Induced Pneumonitis and Myocardial Injury in A Young Bodybuilder.
Article in European journal of case reports in internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anabolic-androgenic steroids (AAS) are frequently misused by athletes to increase muscle mass and performance, and their toxicity affects multiple organ systems. This case describes cardiopulmonary complications. Case description: We report a 29-year-old competitive bodybuilder who presented with cough, haemoptysis, exertional dyspnoea, and fatigue after escalating AAS use before a competition. Investigations revealed systemic inflammation, bilateral pulmonary ground-glass opacities, pleural effusions, and myocardial oedema with pericardial involvement. Anti-glomerular basement membrane antibodies were tested to exclude Goodpasture's syndrome, tuberculosis was excluded (GeneXpert and multiplex biomarker test negative), and polymerase chain reaction testing for coronavirus disease-19 was negative. Lab results showed mildly elevated troponin T (0.08 ng/ml, normal <0.014), supporting myocardial injury. Cultures of blood and sputum showed no pathogenic growth, and antinuclear antibodies (ANA) were negative.The patient received empirical antibiotics, corticosteroids, and diuretics, with marked clinical improvement within 72 hours. Oral corticosteroid therapy was tapered over 7 days. Follow-up computed tomography scan of the chest 7 days later showed complete resolution of pleural effusions and ground-glass opacities. Echocardiography revealed resolution of pericardial effusion and normalization of myocardial appearance coinciding with sustained cessation of AAS. At 6-month follow-up, the patient had discontinued anabolic steroid use, remained clinically well, and resumed recreational sports. Conclusion: This case demonstrates that AAS misuse may cause combined pulmonary and cardiac complications. Although infection cannot be fully excluded due to concurrent antibiotics, negative cultures, ANA, and Anti-GBM results support the interpretation that AAS was the primary cause of pneumonitis and myocardial injury. Improvement after cessation of AAS strengthens the causal link, supported by existing literature. LEARNING POINTS: Anabolic-androgenic steroids (AAS) can cause serious multisystem toxicity, including pulmonary and cardiac complications, even in young athletes.AAS misuse should be considered in the differential diagnosis of unexplained ground-glass opacities and myocardial injury in otherwise healthy individuals.Detailed substance history is often difficult to obtain from patients, underscoring the need for a high index of suspicion.Early recognition and cessation of AAS use can lead to clinical and radiological improvement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.